ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

hyaluronidase (human recombinant)

Also written as “Efgartigimod PH20 SC”, “efgartigimod PH20 SC” and “rHuPH20”.

Its studies are mostly in Diabetes Mellitus, Type 1 · Myasthenia Gravis · Primary Immunodeficiency Diseases · Dehydration · Multiple Myeloma, led by 7 companies.

Drug pageHyaluronidase (human recombinant): every studyMany companies study it; this page follows only the 57 they lead. All 69 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 7, 202457 company-led studies, 14 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
argenxits history only2211 open or runningphase 4since Oct 7, 2024Feb 20, 2020Mar 2027phase 2 · NCT06655155
Halozyme Therapeutics200 open or runningphase 4since Apr 4, 2006Apr 4, 2006none ahead
Takedaits history only60 open or runningphase 3since Dec 23, 2008Oct 29, 2008none ahead
Hoffmann-La Rocheits history only42 open or runningphase 2since Sep 11, 2017Sep 11, 2017Aug 31, 2029phase 2 · NCT07503340
Baxter Healthcareits history only30 open or runningphase 4since Dec 10, 2008Dec 10, 2008none ahead
Fosun Pharmaits history only11 open or runningphase 1since Feb 24, 2026Feb 24, 2026none ahead
Johnson & Johnsonits history only10 open or runningphase 1since Aug 6, 2015Aug 6, 2015none ahead

Also a collaborator on its studies: BioLineRx.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Halozyme Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Apr 4, 2006.

  1. Apr 3, 2008Phase 4 study in HealthyNCT00656370 · 15 enrolled · United States
  2. Oct 15, 2008Phase 2 study in Diabetes Mellitus, Type 1NCT00774800 · 22 enrolled · United States
  3. Oct 15, 2008Phase 4 study in DehydrationNCT00773175 · 148 enrolled · United States
  4. Oct 29, 2008Phase 1 study in Non-Muscle Invasive Bladder NeoplasmsNCT00782587 · 14 enrolled · United States
  5. Dec 11, 2008Phase 1 study in Risk Factors for or a Diagnosis of OsteoporosisNCT00807963 · 31 enrolled · United States
  6. Mar 13, 2009Phase 1 study in Diabetes MellitusNCT00862849 · 22 enrolled · United States
  7. Apr 15, 2009Phase 2 study in Diabetes Mellitus, Type 1NCT00883558 · 48 enrolled · United States
  8. Jun 5, 20092 phase 2 studiesNCT00916357, NCT00928447
  9. Sep 17, 2009Phase 1 study in Insulin ResistanceNCT00979875 · 14 enrolled · United States
  10. Aug 31, 20102 phase 2 studiesNCT01194258, NCT01194245
  11. Jan 10, 2011Phase 1 study in Diabetes Mellitus, Type 1NCT01275131 · 45 enrolled · United States
  12. Jan 31, 2012Phase 4 study in Diabetes Mellitus, Type 1NCT01526733 · 25 enrolled · United States
  13. Apr 3, 2012Phase 1 study in HealthyNCT01572012 · 12 enrolled · United States
  14. Apr 29, 2013Phase 4 study in Diabetes Mellitus, Type 1NCT01848990 · 456 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 20 Halozyme Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01848990Diabetes Mellitus, Type 1 · United States4CompletedFeb 2014456
NCT01572012Healthy · United States1CompletedNov 201312
NCT01526733Diabetes Mellitus, Type 1 · United States4CompletedAug 201225
NCT01275131Diabetes Mellitus, Type 1 · United States1CompletedDec 201145
NCT01194258Diabetes Mellitus, Type 2 · United States2CompletedAug 2011132
NCT01194245Diabetes Mellitus, Type 1 · United States2CompletedAug 2011135
NCT00979875Insulin Resistance · United States1CompletedFeb 201014
NCT00928447Dermatitis, Allergic Contact · United States2CompletedSep 13, 200922
NCT00916357Diabetes Mellitus, Type 2 · United States2CompletedNov 200923
NCT00883558Diabetes Mellitus, Type 1 · United States2CompletedFeb 201048
NCT00862849Diabetes Mellitus · United States1CompletedJun 200922
NCT00807963Risk Factors for or a Diagnosis of Osteoporosis · United States1CompletedSep 21, 200931
NCT00782587Non-Muscle Invasive Bladder Neoplasms · United States1CompletedMar 200914
NCT00774800Diabetes Mellitus, Type 1 · United States2CompletedMar 200922
NCT00773175Dehydration · United States4CompletedNov 2009148
NCT00656370Healthy · United States4CompletedJan 30, 200815
NCT00593281Pain · United States3CompletedOct 200613
NCT00435604Healthy1Completed15
NCT00318643Urinary Bladder Neoplasms · United States2CompletedAug 11, 200927
NCT00311519Healthy · United States4Completed50

How it is read

Names in the registry

  • “Efgartigimod PH20 SC”, 12 entries
  • “efgartigimod PH20 SC”, 10 entries
  • “rHuPH20”, 5 entries
  • “Recombinant human hyaluronidase PH20 (rHuPH20)”, 4 entries
  • “recombinant human hyaluronidase”, 3 entries

Codes read as this program: RHUPH20.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.